Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 473

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 473
---
ZCUBE LLC, except to the extent of his pecuniary interest therein.                                                                                                                                                         |

| (20) | Consists of an aggregate of (i) 4,577,000 shares to be purchased in the PIPE Offering; (ii) 7,806,908                                                                                                                                    
 shares of common stock; (iii) 2,160,585 shares issuable upon the exercise of stock options within 60 days of January 30, 2025; and (iv); 35,500 shares issuable upon the vesting of restricted stock units within 60 days of January 30, 
 2025 held by our current executive officers and directors as a group.                                                                                                                                                                    |

- 321 -

ADDITIONAL INFORMATION

Transaction of Other Business

The board of directors
knows of no other matters that will be presented for consideration at the Special Meeting. If any other matters are properly brought before the Special Meeting, the persons acting as proxies intend to vote the shares represented thereby in
accordance with their best judgment on such matters, under applicable laws.

Householding

We have adopted a procedure approved by the SEC called “householding,” under which we can deliver a single copy of the notice and proxy statement,
and proxy materials, to multiple stockholders who share the same address unless we receive contrary instructions from one or more stockholders.

This
means that only one copy of the notice and proxy statement, and proxy materials, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document upon written or oral request to Aadi
Bioscience, Inc., 17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272, Attention: Corporate Secretary, telephone: (424) 744-8055. If you want to receive separate copies of Notice and proxy
statement, and proxy materials to stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you may contact us at the above address and phone number. Street name stockholders may
contact their broker, bank or other nominee to request information about householding.

Stockholder Communications

The board of directors provides to every securityholder the ability to communicate with the board of directors, as a whole, and with individual directors on
the board of directors through an established process for securityholder communication. For a securityholder communication directed to the board of directors as a whole, securityholders may send such communication to the